(GALD) Galderma N - Ratings and Ratios
Injectable Aesthetics, Dermatological Skincare, Therapeutic Dermatology
GALD EPS (Earnings per Share)
GALD Revenue
Description: GALD Galderma N
Galderma Group AG is a dermatology-focused company with a diverse portfolio of brands and services across injectable aesthetics, dermatological skincare, and therapeutic dermatology. The companys flagship brands include Restylane, Dysport/Azzalure, and Soolantra, among others, which cater to a wide range of dermatological needs.
From a market perspective, Galderma operates in the specialty pharmaceutical industry, which is characterized by high growth potential driven by increasing demand for dermatological treatments. The companys strong brand portfolio and global presence position it well for future growth. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and research and development (R&D) pipeline progress.
Analyzing Galdermas financials, the companys market capitalization stands at approximately CHF 27.97 billion, indicating a significant presence in the market. The price-to-earnings (P/E) ratio of 154.34 suggests high expectations for future earnings growth. The forward P/E ratio of 53.19 indicates a potential decrease in earnings growth rate in the near future. Return on Equity (RoE) is relatively low at 2.28%, which may indicate underutilization of shareholder equity or high equity levels.
To further evaluate Galdermas potential, its essential to examine its revenue diversification across different product categories, geographic regions, and customer segments. A strong R&D pipeline with innovative products in the dermatology space could be a key driver of future growth. Additionally, monitoring the competitive landscape and market trends in the dermatology industry will be crucial in assessing Galdermas long-term prospects.
GALD Stock Overview
| Market Cap in USD | 41,750m |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO / Inception |
GALD Stock Ratings
| Growth Rating | 91.9% |
| Fundamental | 60.1% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | 53.2% |
| Analyst Rating | - |
GALD Dividends
| Dividend Yield 12m | 0.12% |
| Yield on Cost 5y | 0.28% |
| Annual Growth 5y | % |
| Payout Consistency | 1.0% |
| Payout Ratio | 11.5% |
GALD Growth Ratios
| Growth Correlation 3m | 95.8% |
| Growth Correlation 12m | 79.1% |
| Growth Correlation 5y | 91.1% |
| CAGR 5y | 101.05% |
| CAGR/Max DD 5y | 2.61 |
| Sharpe Ratio 12m | 1.75 |
| Alpha | 63.82 |
| Beta | 0.786 |
| Volatility | 28.59% |
| Current Volume | 436.2k |
| Average Volume 20d | 256.6k |
| Stop Loss | 140.3 (-3%) |
| Signal | 2.75 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (396.7m TTM) > 0 and > 6% of Revenue (6% = 383.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.93% (prev 0.84%; Δ 4.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 977.4m > Net Income 396.7m (YES >=105%, WARN >=100%) |
| Net Debt (2.30b) to EBITDA (872.4m) ratio: 2.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (237.8m) change vs 12m ago 0.11% (target <= -2.0% for YES) |
| Gross Margin 69.37% (prev 70.07%; Δ -0.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.27% (prev 43.75%; Δ 11.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.66 (EBITDA TTM 872.4m / Interest Expense TTM 389.6m) >= 6 (WARN >= 3) |
Altman Z'' 3.24
| (A) 0.02 = (Total Current Assets 1.84b - Total Current Liabilities 1.53b) / Total Assets 12.62b |
| (B) 0.45 = Retained Earnings (Balance) 5.68b / Total Assets 12.62b |
| (C) 0.06 = EBIT TTM 646.2m / Avg Total Assets 11.55b |
| (D) 1.18 = Book Value of Equity 5.68b / Total Liabilities 4.83b |
| Total Rating: 3.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.05
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 0.96% = 0.48 |
| 3. FCF Margin 5.40% = 1.35 |
| 4. Debt/Equity 0.34 = 2.44 |
| 5. Debt/Ebitda 3.06 = -1.85 |
| 6. ROIC - WACC -1.96% = -2.45 |
| 7. RoE 6.09% = 0.51 |
| 8. Rev. Trend 47.19% = 2.36 |
| 9. Rev. CAGR 92.73% = 2.50 |
| 10. EPS Trend 68.65% = 1.72 |
| 11. EPS CAGR 3481 % = 2.50 |
What is the price of GALD shares?
Over the past week, the price has changed by +3.65%, over one month by +12.69%, over three months by +27.71% and over the past year by +82.68%.
Is Galderma N a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GALD is around 160.77 CHF . This means that GALD is currently undervalued and has a potential upside of +11.11% (Margin of Safety).
Is GALD a buy, sell or hold?
What are the forecasts/targets for the GALD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 140.4 | -2.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 178.9 | 23.6% |
GALD Fundamental Data Overview
Market Cap CHF = 33.58b (33.58b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 175.0m CHF (last quarter)
P/E Trailing = 111.7188
P/E Forward = 42.1941
P/S = 7.1599
P/B = 5.2735
P/EG = 1.0051
Beta = None
Revenue TTM = 6.39b CHF
EBIT TTM = 646.2m CHF
EBITDA TTM = 872.4m CHF
Long Term Debt = 2.64b CHF (from longTermDebt, last quarter)
Short Term Debt = 36.0m CHF (from shortTermDebt, last quarter)
Debt = 2.67b CHF (Calculated: Short Term 36.0m + Long Term 2.64b)
Net Debt = 2.30b CHF (from netDebt column, last quarter)
Enterprise Value = 36.08b CHF (33.58b + Debt 2.67b - CCE 175.0m)
Interest Coverage Ratio = 1.66 (Ebit TTM 646.2m / Interest Expense TTM 389.6m)
FCF Yield = 0.96% (FCF TTM 344.7m / Enterprise Value 36.08b)
FCF Margin = 5.40% (FCF TTM 344.7m / Revenue TTM 6.39b)
Net Margin = 6.21% (Net Income TTM 396.7m / Revenue TTM 6.39b)
Gross Margin = 69.37% ((Revenue TTM 6.39b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Tobins Q-Ratio = 6.35 (Enterprise Value 36.08b / Book Value Of Equity 5.68b)
Interest Expense / Debt = 0.49% (Interest Expense 13.0m / Debt 2.67b)
Taxrate = 25.48% (79.0m / 310.0m)
NOPAT = 481.6m (EBIT 646.2m * (1 - 25.48%))
Current Ratio = 1.21 (Total Current Assets 1.84b / Total Current Liabilities 1.53b)
Debt / Equity = 0.34 (Debt 2.67b / last Quarter total Stockholder Equity 7.79b)
Debt / EBITDA = 3.06 (Net Debt 2.30b / EBITDA 872.4m)
Debt / FCF = 7.75 (Debt 2.67b / FCF TTM 344.7m)
Total Stockholder Equity = 6.51b (last 4 quarters mean)
RoA = 3.14% (Net Income 396.7m, Total Assets 12.62b )
RoE = 6.09% (Net Income TTM 396.7m / Total Stockholder Equity 6.51b)
RoCE = 7.06% (Ebit 646.2m / (Equity 6.51b + L.T.Debt 2.64b))
RoIC = 6.32% (NOPAT 481.6m / Invested Capital 7.62b)
WACC = 8.28% (E(33.58b)/V(36.25b) * Re(8.91%)) + (D(2.67b)/V(36.25b) * Rd(0.49%) * (1-Tc(0.25)))
Shares Correlation 5-Years: 100.0 | Cagr: 0.11%
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.68% ; FCFE base≈221.7m ; Y1≈273.5m ; Y5≈466.6m
Fair Price DCF = 28.72 (DCF Value 6.75b / Shares Outstanding 234.8m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 47.19 | Revenue CAGR: 92.73%
Rev Growth-of-Growth: 42.73
EPS Correlation: 68.65 | EPS CAGR: 3481 %
EPS Growth-of-Growth: 92.01